Article
Induction therapy with dabrafenib, trametinib, and PD-1 inhibitor and surgical conversion in unresectable stage III non-small cell lung cancers with BRAF V600E mutation: 2 cases.
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2025
Cheng Sida, Zhang Ruijie, Yang Feng, Li Jianfeng, Zhao Huimin, Zhou Lixin, Chang Geyun, Sun Kunkun, Zhang Min, Yan Xiang, Yang Fan
Abstract excerpt
Chemoradiotherapy followed by consolidative immunotherapy is the standard-of-care for unresectable stage III non-small cell lung cancers (NSCLC), yet confers limited benefit in those with driver mutations, BRAF-V600x included. Here, we report two cases of unresectable stage III NSCLC harboring BRAF V600E mutation treated with induction dabrafenib, trametinib, and a PD-1 inhibitor. Both patients exhibited...
Read the complete abstract on PubMedTopics
- Humans
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Imidazoles
- Lung Neoplasms